Receipt date: 01/25/2006

IAP5 Rec'd PCT/PTO 02554AN-20061: 1611 MODIFIED PTO/SB/08 A & B (06-03)

			C	Complete if Known		
Confirmation Number Unknew 20285  INFORMATION DISCLOSURE Filing Date January 25, 2006	Base on C 11P/4/110800					
		NOGLOCUBE	Confirmation Number	Ufficial プレンとうし		
•	STATEMENT BY APPLICANT		Filing Date	January 25, 2006		
	STATEMENT BY	APPLICANT	First Named Inventor	Junya TOGUCHIDA		
	(use as many sheet	s as nacessarul	Art Unit	Unknown		
	(use as many sneed	s us necessuryy	Examiner Name	Unknown		
Sheet	1	of 1	Attorney Docket Number	Q92863		

_	-		U.S	S. PATENT DOCU	MENTS
		Document Number			
Examiner Initials*	Cite No. <sup>1</sup>	Number Kind  Number Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentce or Applicant of Cited Document	
		US 6,133,230	Α	10-17-2000	UNIV. QUEENS KINGSTON

				FOREIGN PA	ATENT DOCUME	NTS	
Examiner	Cite	Foreign Patent Document			Publication Date	Name of Patentee or	Translation <sup>6</sup>
Initials* No.1	No.1	Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation
		WO	03/45371	A1	06-05-2003	PFIZER PROD. INC.	
000000000000000000000000000000000000000	000000000000000000000000000000000000000		2001-220357	000940000000000000000000000000000000000	08 14 2001		000000000000000000000000000000000000000
		wo	98/58911	A2	12-30-1998	PFIZER INC	
200000000000000000000000000000000000000	200000000000000000000000000000000000000	J.D	2000 507061	,,A <sub>2</sub>	06 27 2000	PEIZEP INC	.00000000000000000000000000000000000000
		- December of the second	2001-220357		088 14 2001	Pfizer Products Inc	000000000000000000000000000000000000000
000000000000000000000000000000000000000	000000000000000000000000000000000000000	J.D	11-193268	>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>	07-21-1999	One Pharmaceutical Co., Ltd.	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
		wo	02/92064	A2	11-21-2002	MEDICAL RES COUNCIL	
	000000000000000000000000000000000000000	·····	2001-527063	000001000000000000000000000000000000000	12-25-2001		000000000000000000000000000000000000000
***************************************	000000000000000000000000000000000000000	J.P.	2000 95755	~~	04 04 2000	One Pharmaceutical Co., Ltd.	000000000000000000000000000000000000000
000000000000000000000000000000000000000			2000 128858		05.09.2000	One Pharmaceutical Co., Ltd.	***************************************
*******************************	000000000000000000000000000000000000000	WO	08/3/1016	A.1	08-13-1998	ONO PHARM CO LTD	***************************************
200000000000000000000000000000000000000		P	2002 179595	<u>A</u>	06 36 3003	Pfizer Products Inc	
	XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX	Į.	6 227985		08 16 1004	GD Searle & Co	
000000000000000000000000000000000000000	>00000000000000000000000000000000000000	WQ	02/16311	A.1	02-28-2002	ONO PHARM CO LTD	***************************************
ASSA ASSA ASSA ASSA ASSA ASSA ASSA ASS	***************************************	WO	02/20462	Antonomico	03-14-2002	ONO PHARWCO ATD:	***
200000000000000000000000000000000000000	700000000000000000000		03/16254	<u></u>	02 27 2002	ONO PHARM COLTD	

		NON PATENT LITERATUR						
Examiner   Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.						
		AJ DE-BRUM-FERNANDES, et al., "Characterization chondrocytes in culture", Br. J. Pharmacol., 1996, pp. 15		ype in bovine				
		VM PARALKAR, et al., "An EP2 receptor-selective pro- Natl. Acad. Sci. USA, May 27, 2003, pp. 6736-6740	ostaglandin E2 agonist ind	uces bone healing", Proc.				
		F DEL TORO JR, et al., "Characteriztion of prostagland (2)2(3)-mediated effects on resting zone chrondrocytes" 2	in E(2) receptors and their , J. Cell. Physiol., 2000, p	r role in 24,25-(OH) p. 196-208, Vol. 182, No.				
		U. SUZUWA, et al., "The role of prostaglandin E recept resorption: an analysis using specific agonists for the res 1559, Vol. 141, No. 4						
		E. ROSADO, et al., "Transforming growth factor-β1 regulation of growth zone chondrocytes is mediated by multiple interacting pathways.", Biochim. Biophys. Acta, 2002, pp. 1-15, Vol. 1590, No. 1-3						
		VL SYLVIA, et al., "Transforming growth factor-β1 regulation of resting zone chondrocytes is mediated by two separate but interacting pathways.", Biochim. Biophys. Acta, 2000, pp/311-324, Vol. 1496, No. 2-3						
		VL SYLVIA, et al., "Characterization of PGE <sub>2</sub> receptors (EP) and their role as mediators of 1α,25-(OH) <sub>2</sub> D <sub>3</sub> effects on growth zone chondrocytes.", J. Steroid Biochem. Mol. Biol., 2001, pp. 261-274, Vol. 78, No.3						
		JM MCCOY, et al. "The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis.", J. Clin. Invest., 2002, pp. 651-658, Vol. 110, No. 5						
Examiner Sig	nature	/Joseph Kudla/	Date Considered	06/30/2008				

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to indicate here if English